期刊文献+

冠心病患者载脂蛋白AI基因多态性的研究 被引量:2

Studies on the association of apolipoprotein AI gene polymorphism with coronary heart disease
下载PDF
导出
摘要 目的 探讨载脂蛋白 AI (Apo AI)基因多态性与冠心病的关系。方法 经冠状动脉造影选择对照组(1 82例 )和冠心病组 (4 62例 ) ,应用 PCR,Msp I内切酶消化及 PAGE的方法确定 Apo AI基因多态性。结果 冠心病组和对照组均以 M1 + + 、M2 + + 基因型最常见 ,M1 + - 次之 ,两组比较均无显著性差异 (P>0 .0 5 )。冠心病组 M1 - - 、M2 + -基因型频率明显高于对照组 ,并且随着病变冠脉的数量增加而增加 (P<0 .0 2 5~ 0 .0 0 5 )。各冠心病亚组中 ,两种 Apo AI基因多态性并存的频率高于对照组 ,3支病变组与对照组、 1支病变组比较 ,差异有显著性 (P<0 .0 5~ 0 .0 2 5 )。结论 Apo Objective To explore the association of apolipoprotein AI(ApoAI)gene polymorphism with coronary heart disease(CHD).Methods Four hundred and Sixty two patients with CHD and 182 non CHD as controls that were determined by coronary angiography.Polymerase chain reaction(PCR),MspI digestion,polyacrylamide gel electrophoresis,and silver staining were used for the detection of ApoAI genotype.Results The M1 ++ and M2 ++ genotypes were most common in patients with CHD and controls.There were no differences between two groups(p>0.05).The frequencies of the M1 -,M2 +- genotypes in CHD group were significantly higher than those of control group(p<0.025~0.005),and they increased linearly with the number of diseased vessels.The frequency of combination with two polymorphism(M1 +- ,M1 -- and M2 +- )in CHD subgroups was higher than that of controls.Patients with three diseased vessels had significantly higher frequency of combination of two polymorphism than those with no diseased vessel and single vessel(p<0 05~0 025).Conclusions These results suggest that ApoAI gene polymorphism is involved in the occurrence and the severity of CHD.
出处 《心脑血管病防治》 2001年第2期10-12,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
关键词 冠心病 载脂蛋白AI 基因多态性 相关性 Coronary disease Apolipoprotein AI Polymorphism
  • 相关文献

参考文献9

  • 1Wang XL,Badenhop R,Humphrey K,etal.C to T and G to A transitions are respensible for loss of a MspI restriction site inthe 5'-region of the human apolipoprotein AI gene.Hum.Genet,1995,95:473-475.
  • 2Assman G,Von Eckardstein A,Funke H.HDL and reverse transport ofcholesterol:insights from mutants.In:Galton DJ,Assman G,eds.DNA polymorphisms as diseasemarkers.New York:Plenum Press,1991,61-70.
  • 3Matsunaga T,Hiasa Y,Yanagi H,et al.Apolipoprotein A-I deficiency due to a codon 84nonsense mutation of the apolipoprotein A-I gene.Proc Natl Acad Sci USA,1991,88:2793-2797.
  • 4Sorci-Thomas M,Prack MM,Dashti N,et al.Apolipoprotein(apo) AI production and mRNAabundance explain plasma apo A-I and high density lipoprotein differences between twononhuman primates species with high and low susceptibilities to diet-induced hypercholesterolemia.J Biol Chem,1988,263:5183-5189.
  • 5Papazafiri P,Ogami K,Ramji DP,et al.Promoter elements and factors involved inhepatic transcription of the human apo AI gene positive and negative regulators bind tooverlapping sites.J Biol Chem,1991,266:5790-5797.
  • 6Falcone D,Andrews DW.Both the 5' untranslated region and the sequences surroundingthe start site contribute to efficient initiation of translation in vitro.Mol CellBiol,1991,11:2656-2664.
  • 7Angotti E,Mele E,costanzo F,et al.A polymorphism(G to A transtion) in the -78position of apolipoprotein AI promoter increases transcription efficiency.J BiolChem,1994,269:17371-17374.
  • 8Wang XL,Badenhop R,Humphrey K,et al.New MspI polymorphism at +83bp of the humanapolipoprotein AI gene:association with increased circulating high density lipoproteincholesterol levels.Genet Epidemiol,1996,13:1-10.
  • 9Smith JD,Brinton EA,Breslow JL.Polymorphism in the human apolipoprotein AI genepromoter region.Association of the minor allele with decreased production rate in vivo andpromoter activity in vitro.J Clin Invest,1992,89:1790-1800.

同被引文献3

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部